H.L.M. Brus - Concepedia

Author

H.L.M. Brus

Medisch Spectrum Twente ORCID

Also Known As

Erwin R. Seydel, H L Brus, H L M Brus, H. Brus, H. L. M. Brus, H.L.M. Brus, Herman L M Brus, Hope Brus

Publications

758

Citations

H-Index

Concepts

All Affiliations

Medisch Spectrum Twente Radboud University Medical Center Radboud University Nijmegen Medisch Centrum Leeuwarden Sint Maartenskliniek

About

H.L.M. Brus is an author at Medisch Spectrum Twente specializing in immunology, hla, and epidemiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	10
2	Public Health	1	1	10
3	Epidemiology	1	1	10
4	Immunology	1	1	10
5	Pathology	1	1	10

H.L.M. Brus

Publications

557

Citations

H-Index

Page 1

	Year	Citations
Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis H.L.M. Brus, M.A.F.J. van de Laar, Erik Taal, Annals of the Rheumatic Diseases	1998	133
The effectiveness and medication costs of three anti-tumour necrosis factor Î± agents in the treatment of rheumatoid arthritis from prospective clinical practice data Wietske Kievit, Eddy Adang, Jaap Fransen, Annals of the Rheumatic Diseases	2008	117
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial Cornelia H.M. van Jaarsveld, Johannes W G Jacobs, M. J. Van Der Veen, Annals of the Rheumatic Diseases	2000	92
The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion Maarten H. Vermeer, H. H. Kuper, A. E. van der Bijl, Lara D. Veeken	2012	60
Toxicity of anti‐rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis Cornelia H.M. van Jaarsveld, Z N Jahangier, J. W. G. Jacobs, Lara D. Veeken	2000	49
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry S. A. A. van Dartel, Jaap Fransen, Wietske Kievit, Lara D. Veeken	2013	44
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice M. Blom, Wietske Kievit, H. H. Kuper, Arthritis Care & Research	2010	36
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies Wietske Kievit, Jaap Fransen, Eddy Adang, Annals of the Rheumatic Diseases	2008	16
Is there an indication for HLA-DR typing for individual patients with rheumatoid arthritis? Cornelia H.M. van Jaarsveld, Henny G. Otten, J. W. G. Jacobs, PubMed HlaIndividual PatientsGenetic EpidemiologyDiagnosisPathology	1998	10

Page 1